GlassScriptPhysician profile
Brian J Hansen
NPI 1609306968
$1,881.01
in general payments reported to CMS, 2019-2025
27 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.81 · 2021: $170 · 2022: $289 · 2023: $155 · 2024: $606 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.27 | 2021-2025 | |
| Novo Nordisk INC | $171.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $151.84 | 2024-2025 | Veozah |
| Lilly USA, LLC | $151.70 | 2020-2025 | Zepbound, Mounjaro, Emgality |
| Exelixis INC. | $125.00 | 2022 | |
| Pfizer INC. | $94.39 | 2021-2025 | |
| Amgen INC. | $87.81 | 2024-2025 | Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $77.68 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $76.16 | 2022-2023 | |
| Exact Sciences Corporation | $63.83 | 2024-2025 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $61.23 | 2023 | Amvuttra |
| Xeris Pharmaceuticals, INC. | $46.76 | 2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $43.79 | 2024-2025 | Farxiga, Airsupra |
| Inspire Medical Systems, INC. | $41.98 | 2024 | Inspire |
| Viatris Specialty LLC | $38.80 | 2025 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $37.95 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $36.61 | 2024-2025 | Spravato |
| Abbott Laboratories | $35.47 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.30 | 2022 | |
| Vanda Pharmaceuticals INC. | $28.15 | 2024 | Fanapt |
| Medtronic, INC. | $27.70 | 2023-2024 | Minimed 780g |
| Glaxosmithkline, LLC. | $26.51 | 2022 | |
| Tandem Diabetes Care, INC. | $26.02 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $19.06 | 2021 | |
| Vapotherm INC | $16.79 | 2022 | |
| Dexcom, INC. | $14.62 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.